Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gadomelitol
- Development stage
- Unknown
- Lead developer
- Guerbet
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gadomelitol (P792, brand name Vistarem) is a monogadolinated MRI blood-pool contrast agent with a molecular diameter of approximately 5 nm and a molecular weight of about 6.5 kDa. It is designed for magnetic resonance imaging (MRI) applications and exhibits pharmacokinetic and biodistribution profiles consistent with its size, providing prolonged vascular residence and enhanced blood-pool contrast for imaging vascular structures and perfusion. Gadomelitol is part of a class of macromolecular gadolinium-based MRI contrast agents.
- Brand names
- Vistarem
- Other names
- gadomelitolP792P-792P 792
Beyond the preview
Go deeper on gadomelitol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gadomelitol.